AYTU BIOPHARMA, INC Operating Expenses
AYTU BIOPHARMA, INC (AYTU) reported Operating Expenses of $45.13 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-09-22
- AYTU BIOPHARMA, INC operating expenses for the quarter ending 2026-06-30 was $11.19M, a 37.43% decline year-over-year.
- AYTU BIOPHARMA, INC operating expenses for the quarter ending 2026-03-31 was $11.66M, a 12.31% increase year-over-year.
- AYTU BIOPHARMA, INC operating expenses for the quarter ending 2025-12-31 was $11.59M, a 7.11% decline year-over-year.
- AYTU BIOPHARMA, INC operating expenses for the quarter ending 2025-09-30 was $10.69M, a 17.23% decline year-over-year.
- AYTU BIOPHARMA, INC operating expenses for fiscal 2026 was $45.13M, a 15.89% decline from fiscal 2025.
- AYTU BIOPHARMA, INC operating expenses for fiscal 2025 was $53.66M, a 5.95% increase from fiscal 2024.
- AYTU BIOPHARMA, INC operating expenses for fiscal 2024 was $50.65M, a 39.49% decline from fiscal 2023.
- AYTU BIOPHARMA, INC operating expenses for fiscal 2023 was $83.70M, a 48.40% decline from fiscal 2022.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $11.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $22.85M derived: sum of 2 quarters · filed 2026-09-22 | $34.44M derived: sum of 3 quarters · filed 2026-09-22 | $45.13M 10-K · filed 2026-09-22 | ||||
| 2026-03-31 | $11.66M 10-Q · filed 2026-05-13 | $23.26M derived: sum of 2 quarters · filed 2026-05-13 | $33.95M 10-Q · filed 2026-05-13 | $51.82M derived: sum of 4 quarters · filed 2026-09-22 | ||||
| 2025-12-31 | $11.59M 10-Q · filed 2026-02-03 | $22.28M 10-Q · filed 2026-02-03 | $40.16M derived: sum of 3 quarters · filed 2026-09-22 | $50.55M derived: sum of 4 quarters · filed 2026-09-22 | ||||
| 2025-09-30 | $10.69M 10-Q · filed 2025-11-13 | $28.57M derived: sum of 2 quarters · filed 2026-09-22 | $38.95M derived: sum of 3 quarters · filed 2026-09-22 | $51.43M derived: sum of 4 quarters · filed 2026-09-22 | ||||
| 2025-06-30 | $17.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $28.26M derived: sum of 2 quarters · filed 2026-09-22 | $40.74M derived: sum of 3 quarters · filed 2026-09-22 | $53.66M 10-K · filed 2026-09-22 | ||||
| 2025-03-31 | $10.38M 10-Q · filed 2026-05-13 | $22.87M derived: sum of 2 quarters · filed 2026-05-13 | $35.78M 10-Q · filed 2026-05-13 | $49.11M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $12.48M 10-Q · filed 2026-02-03 | $25.40M 10-Q · filed 2026-02-03 | $38.72M derived: sum of 3 quarters · filed 2026-02-03 | $50.68M derived: sum of 4 quarters · filed 2026-02-03 | ||||
| 2024-09-30 | $12.91M 10-Q · filed 2025-11-13 | $26.24M derived: sum of 2 quarters · filed 2025-11-13 | $38.20M derived: sum of 3 quarters · filed 2025-11-13 | $49.66M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $13.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $25.28M derived: sum of 2 quarters · filed 2025-09-23 | $36.74M derived: sum of 3 quarters · filed 2025-09-23 | $50.65M 10-K · filed 2025-09-23 | $59.84M 10-K · filed 2024-09-26 | |||
| 2024-03-31 | $11.96M 10-Q · filed 2025-05-14 | $14.16M 10-Q · filed 2024-05-15 | $23.41M derived: sum of 2 quarters · filed 2025-05-14 | $37.32M 10-Q · filed 2025-05-14 | $44.28M 10-Q · filed 2024-05-15 | $55.72M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $11.46M 10-Q · filed 2025-02-12 | $13.84M 10-Q · filed 2024-02-14 | $25.36M 10-Q · filed 2025-02-12 | $30.13M 10-Q · filed 2024-02-14 | $43.76M derived: sum of 3 quarters · filed 2025-02-12 | $65.06M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-09-30 | $13.90M 10-Q · filed 2024-11-13 | $16.29M 10-Q · filed 2023-11-14 | $32.30M derived: sum of 2 quarters · filed 2024-11-13 | $53.60M derived: sum of 3 quarters · filed 2024-11-13 | $77.76M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $18.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $39.70M derived: sum of 2 quarters · filed 2024-09-26 | $63.86M derived: sum of 3 quarters · filed 2024-09-26 | $83.70M 10-K · filed 2024-09-26 | ||||
| 2023-03-31 | $21.30M 10-Q · filed 2024-05-15 | $45.46M derived: sum of 2 quarters · filed 2024-05-15 | $65.30M 10-Q · filed 2024-05-15 | $97.08M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $24.16M 10-Q · filed 2024-02-14 | $24.09M 10-Q · filed 2023-02-21 | $44.00M 10-Q · filed 2024-02-14 | $43.77M 10-Q · filed 2023-02-21 | $75.78M derived: sum of 3 quarters · filed 2024-02-14 | $141.89M derived: sum of 4 quarters · filed 2024-02-14 | ||
| 2022-09-30 | $19.84M 10-Q · filed 2023-11-14 | $19.68M 10-Q · filed 2022-11-14 | $51.62M derived: sum of 2 quarters · filed 2023-11-14 | $117.73M derived: sum of 3 quarters · filed 2023-11-14 | $141.32M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $31.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $97.89M derived: sum of 2 quarters · filed 2023-10-12 | $121.48M derived: sum of 3 quarters · filed 2023-10-12 | $162.19M 10-K · filed 2023-10-12 | $163.84M 10-K · filed 2022-09-27 | |||
| 2022-03-31 | $66.11M 10-Q · filed 2023-05-11 | $67.34M 10-Q · filed 2022-05-16 | $89.70M derived: sum of 2 quarters · filed 2023-05-11 | $130.41M 10-Q · filed 2023-05-11 | $131.09M 10-Q · filed 2022-05-16 | $165.23M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $23.59M 10-Q · filed 2023-02-21 | $63.75M 10-Q · filed 2023-02-21 | $99.12M derived: sum of 3 quarters · filed 2023-02-21 | $124.33M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-09-30 | $40.16M 10-Q/A · filed 2023-02-21 | $75.53M derived: sum of 2 quarters · filed 2023-02-21 | $100.74M derived: sum of 3 quarters · filed 2023-02-21 | $115.21M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-06-30 | $35.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $60.59M derived: sum of 2 quarters · filed 2022-09-27 | $75.06M derived: sum of 3 quarters · filed 2022-09-27 | $88.07M 10-K · filed 2022-09-27 | ||||
| 2021-03-31 | $25.21M 10-Q · filed 2022-05-16 | $39.69M derived: sum of 2 quarters · filed 2022-05-16 | $52.70M 10-Q · filed 2022-05-16 | $65.91M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $14.47M 10-Q · filed 2022-02-14 | $27.48M 10-Q · filed 2022-02-14 | $40.70M derived: sum of 3 quarters · filed 2022-02-14 | $53.65M derived: sum of 4 quarters · filed 2022-02-14 | ||||
| 2020-09-30 | $13.01M 10-Q · filed 2021-11-15 | $17.08M 10-Q · filed 2020-11-12 | $26.23M derived: sum of 2 quarters · filed 2021-11-15 | $39.18M derived: sum of 3 quarters · filed 2021-11-15 | $47.32M derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | $13.21M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | $26.16M derived: sum of 2 quarters · filed 2021-09-28 | $34.31M derived: sum of 3 quarters · filed 2021-09-28 | $40.48M 10-K · filed 2021-09-28 | $48.76M 10-K · filed 2020-10-06 | |||
| 2020-03-31 | $12.95M 10-Q · filed 2020-05-15 | $21.09M derived: sum of 2 quarters · filed 2020-05-15 | $27.27M 10-Q · filed 2020-05-15 | $33.56M derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-12-31 | $8.14M 10-Q · filed 2020-02-14 | $14.32M 10-Q · filed 2020-02-14 | $20.61M derived: sum of 3 quarters · filed 2020-11-12 | $27.29M derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-09-30 | $6.18M 10-Q · filed 2020-11-12 | $12.47M derived: sum of 2 quarters · filed 2020-11-12 | $19.15M derived: sum of 3 quarters · filed 2020-11-12 | $25.49M derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-06-30 | $6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | $12.97M derived: sum of 2 quarters · filed 2020-10-06 | $19.32M derived: sum of 3 quarters · filed 2020-10-06 | $24.17M 10-K · filed 2020-10-06 | ||||
| 2019-03-31 | $6.68M 10-Q · filed 2020-05-15 | $13.02M derived: sum of 2 quarters · filed 2020-05-15 | $17.87M 10-Q · filed 2020-05-15 | $22.62M derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2018-12-31 | $6.35M 10-Q · filed 2020-02-14 | $11.19M 10-Q · filed 2020-02-14 | $15.95M derived: sum of 3 quarters · filed 2020-02-14 | $24.08M derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2018-09-30 | $4.85M 10-Q · filed 2019-11-14 | $9.60M derived: sum of 2 quarters · filed 2019-11-14 | $17.73M derived: sum of 3 quarters · filed 2019-11-14 | $22.78M derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | $4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-26 | $12.88M derived: sum of 2 quarters · filed 2019-09-26 | $17.93M derived: sum of 3 quarters · filed 2019-09-26 | $23.36M 10-K · filed 2019-09-26 | ||||
| 2018-03-31 | $8.13M 10-Q · filed 2019-05-14 | $13.18M derived: sum of 2 quarters · filed 2019-05-14 | $18.61M 10-Q · filed 2019-05-14 | $18.61M 10-Q · filed 2018-05-14 | $24.55M derived: sum of 4 quarters · filed 2019-05-14 | |||
| 2017-12-31 | $5.05M 10-Q · filed 2019-05-14 | $10.48M 10-Q · filed 2019-05-14 | $16.41M derived: sum of 3 quarters · filed 2019-05-14 | $22.17M derived: sum of 4 quarters · filed 2019-05-14 | ||||
| 2017-09-30 | $5.43M 10-Q · filed 2018-11-07 | $11.37M derived: sum of 2 quarters · filed 2018-11-07 | $17.12M derived: sum of 3 quarters · filed 2018-11-07 | $22.11M derived: sum of 4 quarters · filed 2018-11-07 | ||||
| 2017-06-30 | $5.94M derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-06 | $11.69M derived: sum of 2 quarters · filed 2018-09-06 | $16.68M derived: sum of 3 quarters · filed 2018-09-06 | $23.35M 10-K · filed 2018-09-06 | ||||
| 2017-03-31 | $5.75M 10-Q · filed 2018-05-14 | $10.75M derived: sum of 2 quarters · filed 2018-05-14 | $17.41M 10-Q · filed 2018-05-14 | $31.65M derived: sum of 4 quarters · filed 2018-05-14 | ||||
| 2016-12-31 | $4.99M 10-Q · filed 2018-02-08 | $11.66M 10-Q · filed 2018-02-08 | $25.89M derived: sum of 3 quarters · filed 2018-02-08 | $29.79M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-09-30 | $6.66M 10-Q · filed 2017-11-09 | $20.90M derived: sum of 2 quarters · filed 2017-11-09 | $24.80M derived: sum of 3 quarters · filed 2017-11-09 | $28.28M derived: sum of 4 quarters · filed 2017-11-09 | ||||
| 2016-06-30 | $14.24M derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-31 | $18.13M derived: sum of 2 quarters · filed 2017-08-31 | $21.62M derived: sum of 3 quarters · filed 2017-08-31 | $24.27M 10-K · filed 2017-08-31 | ||||
| 2016-03-31 | $3.90M 10-Q · filed 2017-05-11 | $7.38M derived: sum of 2 quarters · filed 2017-05-11 | $10.03M 10-Q · filed 2017-05-11 | $12.36M derived: sum of 4 quarters · filed 2017-05-11 | ||||
| 2015-12-31 | $3.48M 10-Q · filed 2017-02-09 | $6.13M 10-Q · filed 2017-02-09 | $8.47M derived: sum of 3 quarters · filed 2017-02-09 | $10.30M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-09-30 | $2.65M 10-Q · filed 2016-11-07 | $4.98M derived: sum of 2 quarters · filed 2016-11-07 | $6.81M derived: sum of 3 quarters · filed 2016-11-07 | $8.43M derived: sum of 4 quarters · filed 2016-11-07 | ||||
| 2015-06-30 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-01 | $4.16M derived: sum of 2 quarters · filed 2016-09-01 | $5.77M derived: sum of 3 quarters · filed 2016-09-01 | $7.89M 10-K · filed 2016-09-01 | ||||
| 2015-03-31 | $1.83M 10-Q · filed 2016-05-11 | $3.44M derived: sum of 2 quarters · filed 2016-05-11 | $5.56M 10-Q · filed 2016-05-11 | |||||
| 2014-12-31 | $1.61M 10-Q · filed 2016-02-11 | $3.73M 10-Q · filed 2016-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |